120 related articles for article (PubMed ID: 2297692)
1. Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice.
Kestell P; Paxton JW; Evans PC; Young D; Jurlina JL; Robertson IG; Baguley BC
Cancer Res; 1990 Feb; 50(3):503-8. PubMed ID: 2297692
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921).
Hardy JR; Harvey VJ; Paxton JW; Evans P; Smith S; Grove W; Grillo-Lopez AJ; Baguley BC
Cancer Res; 1988 Nov; 48(22):6593-6. PubMed ID: 3180070
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.
Paxton JW; Jurlina JL
Cancer Chemother Pharmacol; 1986; 16(3):253-6. PubMed ID: 3754493
[TBL] [Abstract][Full Text] [Related]
4. The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit.
Paxton JW; Evans PC; Hardy JR
Cancer Chemother Pharmacol; 1989; 23(5):291-5. PubMed ID: 2706733
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits.
Paxton JW; Evans PC; Singh RM
Cancer Chemother Pharmacol; 1987; 20(1):13-5. PubMed ID: 3621447
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.
Paxton JW; Kim SN; Whitfield LR
Cancer Res; 1990 May; 50(9):2692-7. PubMed ID: 2328494
[TBL] [Abstract][Full Text] [Related]
7. The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial.
Paxton JW; Hardy JR; Evans PC; Harvey VJ; Baguley BC
Cancer Chemother Pharmacol; 1988; 22(3):235-40. PubMed ID: 3409457
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide.
Baguley BC; Denny WA; Atwell GJ; Finlay GJ; Rewcastle GW; Twigden SJ; Wilson WR
Cancer Res; 1984 Aug; 44(8):3245-51. PubMed ID: 6547635
[TBL] [Abstract][Full Text] [Related]
9. Thiolytic cleavage and binding of the antitumour agent CI-921 in blood.
Kestell P; Paxton JW; Robertson IG; Evans PC; Dormer RA; Baguley BC
Drug Metabol Drug Interact; 1988; 6(3-4):327-36. PubMed ID: 3271644
[TBL] [Abstract][Full Text] [Related]
10. Derivatives of amsacrine: determinants required for high activity against Lewis lung carcinoma.
Baguley BC; Finlay GJ
J Natl Cancer Inst; 1988 Apr; 80(3):195-9. PubMed ID: 3346911
[TBL] [Abstract][Full Text] [Related]
11. The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits.
Paxton JW
J Pharm Pharmacol; 1986 Nov; 38(11):837-40. PubMed ID: 2879015
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography.
Ganta S; Paxton JW; Baguley BC; Garg S
J Pharm Biomed Anal; 2008 Jan; 46(2):386-90. PubMed ID: 17981420
[TBL] [Abstract][Full Text] [Related]
13. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
14. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
15. Effects of a new amsacrine derivative, N-5-dimethyl-9-(2-methoxy-4-methylsulfonylamino)phenylamino-4- acridinecarboxamide, on cultured mammalian cells.
Traganos F; Bueti C; Darzynkiewicz Z; Melamed MR
Cancer Res; 1987 Jan; 47(2):424-32. PubMed ID: 2431770
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice.
Lukka PB; Paxton JW; Kestell P; Baguley BC
Cancer Chemother Pharmacol; 2010 May; 65(6):1145-52. PubMed ID: 19774378
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs.
Cornford EM; Young D; Paxton JW
Cancer Chemother Pharmacol; 1992; 29(6):439-44. PubMed ID: 1568286
[TBL] [Abstract][Full Text] [Related]
18. Elimination kinetics of amsacrine in the rabbit: evidence of nonlinearity.
Paxton JW; Jurlina JL
Pharmacology; 1985; 31(1):50-6. PubMed ID: 3839584
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
Foster BJ; Wiegand RA; LoRusso PM; Baker LH
Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
[TBL] [Abstract][Full Text] [Related]
20. Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
Kestell P; Dunlop IC; McCrystal MR; Evans BD; Paxton JW; Gamage RS; Baguley BC
Cancer Chemother Pharmacol; 1999; 44(1):45-50. PubMed ID: 10367748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
